MacroGenics Provides Update on Corporate Progress and First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Macrogenics (MGNX) Misses Q1 EPS by 29c, Revenues Miss
April 29, 2021 4:59 PM EDTMacrogenics (NASDAQ: MGNX) reported Q1 EPS of ($0.90), $0.29 worse than the analyst estimate of ($0.61). Revenue for the quarter came in at $16.88 million versus the consensus estimate of $27.95 million.
With the recent launch and commercialization of MARGENZA, we are delivering on our vision to provide potentially... More
